Clinical Trials Browser

Not yet recruiting × Interventional × Neoplasm, Residual × Clear all

NCT07392970 2026-04-09

Motixafortide for MRD Sensitization in AML

Phase 2 Not yet recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT07517705 2026-04-08

MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell Lymphoma

Phase NA Not yet recruiting

Lymphoma, Large B-Cell, Diffuse, Neoplasm, Residual

NCT07507318 2026-04-02

DEL-MRD-CHID

Phase 2 Not yet recruiting

Lymphoma, Large B-Cell, Diffuse, Neoplasm, Residual

NCT07247201 2026-03-30

AlloNK1

Phase 1/2 Not yet recruiting

Nasopharyngeal Carcinoma, Neoplasm, Residual

NCT07443592 2026-03-02

LAL-2025

Phase NA Not yet recruiting

LymphoidOther hematologic neoplasm

Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07413146 2026-02-17

Neoadjuvant CAPEOX Versus Upfront Surgery for Locally Advanced Colon Cancer With Elevated CEA: A Single-Center, Open-Label, Randomized Controlled Trial

Phase NA Not yet recruiting

Gastrointestinal

Colonic Neoplasms, Neoplasm, Residual

NCT07350824 2026-01-20

Predictive Value of Minimal Residual Disease for Postoperative Recurrence and Adjuvant PD-1 Inhibitor in HCC

Phase NA Not yet recruiting

Recurrence, Neoplasm, Residual

NCT07301138 2025-12-24

BEBT-908 Plus Chemotherapy Treatment for CR MRD-Positive MEF2D-Rearranged and Pre-B Acute Lymphoblastic Leukemia Patients

Phase 2 Not yet recruiting

LymphoidOther hematologic neoplasm

Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT07264010 2025-12-04

Sorafenib Combined With Venetoclax as Pre-emptive Therapy Strategy for MRD+ AML: a Prospective, Single-arm, Multicenter Clinical Study

Phase 2/3 Not yet recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT07257380 2025-12-02

MRD-ATLAS

Phase 2 Not yet recruiting

Neoplasm, Residual

NCT06763302 2025-01-08

NGS MRD-Guided Blinatumomab Treatment for Pediatric B-ALL

Phase NA Not yet recruiting

Neoplasm, Residual

NCT06090786 2024-04-10

Kinetics and Impact on Survival of MRD in AML Patients Receiving Azacitidine and Venetoclax

Phase NA Not yet recruiting

Other hematologic neoplasm

Leukemia, Myeloid, Acute, Neoplasm, Residual

NCT06323148 2024-03-21

Adjuvant Target Therapy Guided by ctDNA-MRD in Patients With EGFR-mutant II-IIIA Non-small Cell Lung Cancer (ECTOP-1022)

Phase 3 Not yet recruiting

Lung Neoplasms, Neoplasm, Residual

NCT05427669 2022-10-07

AFFORD

Phase 3 Not yet recruiting

Gastrointestinal

Colorectal Neoplasms, Neoplasm, Residual